黏蛋白阿克曼菌辅助治疗恶性肿瘤的研究进展
作者:
基金项目:

甘肃省非感染性肝病临床医学研究中心(21JR7RA017);甘肃省青年科技基金(21JR7RA012);甘肃省科技厅重点研发计划(20YF8FA099);兰州市人才创新项目(2020RC111)


Akkermansia muciniphila in adjuvant treatment of malignant tumors
Author:
  • TANG Hairu

    TANG Hairu

    The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu, China;Department of Gastroenterology, the 940th Hospital of Joint Logistics Support Forces of Chinese Peoples Liberation Army, Lanzhou 730050, Gansu, China;Laboratory of Preclinical Medicine, the 940th Hospital of Joint Logistics Support Force of Chinese Peoples Liberation Army, Key Laboratory of Stem Cells and Gene Drugs of Gansu Province, Lanzhou 730050, Gansu, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • XIE Youcheng

    XIE Youcheng

    The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu, China;Department of Gastroenterology, the 940th Hospital of Joint Logistics Support Forces of Chinese Peoples Liberation Army, Lanzhou 730050, Gansu, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • LI Na

    LI Na

    The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu, China;Department of Gastroenterology, the 940th Hospital of Joint Logistics Support Forces of Chinese Peoples Liberation Army, Lanzhou 730050, Gansu, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • WANG Pan

    WANG Pan

    Department of Gastroenterology, the 940th Hospital of Joint Logistics Support Forces of Chinese Peoples Liberation Army, Lanzhou 730050, Gansu, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • YU Xiaohui

    YU Xiaohui

    Department of Gastroenterology, the 940th Hospital of Joint Logistics Support Forces of Chinese Peoples Liberation Army, Lanzhou 730050, Gansu, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [62]
  • |
  • 相似文献 [20]
  • | | |
  • 文章评论
    摘要:

    恶性肿瘤是威胁人类健康的全球重大公共卫生问题,多种方法联合,特别是以靶向治疗联合免疫治疗为主的治疗手段,在一定程度延缓了恶性肿瘤的发展,提高了患者的近期生存率,但这些治疗方法并不能覆盖所有患者,远期疗效仍然有限。因此,如何提高患者的生存质量和远期生存率,降低死亡率,成为当前亟待解决的关键问题。近年来越来越多的研究显示肠道微生物的分布与恶性肿瘤的发生、发展密切相关,或可成为治疗恶性肿瘤的新辅助方法,特别是嗜黏蛋白阿克曼菌(Akkermansia muciniphila)的报道较多,然而,关于该菌在恶性肿瘤辅助治疗中安全性和有效性的文献报道尚不多见。因此,本文旨在通过收集近年来嗜黏蛋白阿克曼菌在恶性肿瘤方面的文献,将其研究成果和应用结果进行归纳、分析,以期为临床综合治疗提供一定的药物选择。

    Abstract:

    Malignant tumors are a major global public health problem threatening human health. The combination of multiple therapies, especially targeted therapy combined with immunotherapy, can slow down the progress of malignant tumors and improve the short-term survival rate of the patients. However, these treatment methods cannot cover all patients and have limited long-term efficacy. Therefore, how to improve the quality of life and long-term survival rate and reduce mortality of the patients has become a key problem to be solved. Increasing studies have demonstrated that the distribution of intestinal microorganisms is associated with the occurrence and development of malignant tumors, and regulating intestinal microbiota can serve as a new adjuvant therapy for malignant tumors. Despite the extensive studies about Akkermansia muciniphila in tumor treatment, little is known about the safety and effectiveness of A. muciniphila in the adjuvant treatment of malignant tumors. Therefore, we summarized the research results and application results of A. muciniphila by reviewing the studies on malignant tumors in recent years, aiming to enrich the choices for the comprehensive treatment in clinical practice.

    参考文献
    [1] SIEGEL RL, MILLER KD, FUCHS HE, JEMAL A. Cancer statistics, 2022[J]. CA:a Cancer Journal for Clinicians, 2022, 72(1):7-33.
    [2] SUNG H, FERLAY J, SIEGEL RL, LAVERSANNE M, SOERJOMATARAM I, JEMAL A, BRAY F. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:a Cancer Journal for Clinicians, 2021, 71(3):209-249.
    [3] SENCHUKOVA MA. Helicobacter pylori and gastric cancer progression[J]. Current Microbiology, 2022, 79(12):383.
    [4] SHI YY, ZHENG WX, YANG KT, HARRIS KG, NI KY, XUE L, LIN WB, CHANG EB, WEICHSELBAUM RR, FU YX. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling[J]. The Journal of Experimental Medicine, 2020, 217(5):e20192282.
    [5] SI W, LIANG H, BUGNO J, XU Q, DING XC, YANG KT, FU YB, WEICHSELBAUM RR, ZHAO X, WANG LL. Lactobacillus rhamnosus GG induces cGAS/STING-dependent type I interferon and improves response to immune checkpoint blockade[J]. Gut, 2022, 71(3):521-533.
    [6] ROUTY B, LE CHATELIER E, DEROSA L, DUONG CPM, ALOU MT, DAILLÈRE R, FLUCKIGER A, MESSAOUDENE M, RAUBER C, ROBERTI MP, FIDELLE M, FLAMENT C, POIRIER-COLAME V, OPOLON P, KLEIN C, IRIBARREN K, MONDRAGÓN L, JACQUELOT N, QU B, FERRERE G, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371):91-97.
    [7] SHI LL, SHENG JY, CHEN GZ, ZHU P, SHI CP, LI B, PARK C, WANG JY, ZHANG BX, LIU Z, YANG XL. Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance[J]. Journal for Immunotherapy of Cancer, 2020, 8(2):e000973.
    [8] DEROSA L, ROUTY B, THOMAS AM, IEBBA V, ZALCMAN G, FRIARD S, MAZIERES J, AUDIGIER-VALETTE C, MORO-SIBILOT D, GOLDWASSER F, SILVA CAC, TERRISSE S, BONVALET M, SCHERPEREEL A, PEGLIASCO H, RICHARD C, GHIRINGHELLI F, ELKRIEF A, DESILETS A, BLANC-DURAND F, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer[J]. Nature Medicine, 2022, 28(2):315-324.
    [9] DERRIEN M, COLLADO MC, BEN-AMOR K, SALMINEN S, de VOS WM. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract[J]. Applied and Environmental Microbiology, 2008, 74(5):1646-1648.
    [10] DERRIEN M, VAUGHAN EE, PLUGGE CM, de VOS WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium[J]. International Journal of Systematic and Evolutionary Microbiology, 2004, 54(5):1469-1476.
    [11] DERRIEN M, van PASSEL MW, van de BOVENKAMP JH, SCHIPPER RG, de VOS WM, DEKKER J. Mucin-bacterial interactions in the human oral cavity and digestive tract[J]. Gut Microbes, 2010, 1(4):254-268.
    [12] ASHRAFIAN F, BEHROUZI A, SHAHRIARY A, AHMADI BADI S, DAVARI M, KHATAMI S, RAHIMI JAMNANI F, FATEH A, VAZIRI F, SIADAT SD. Comparative study of effect of Akkermansia muciniphila and its extracellular vesicles on Toll-like receptors and tight junction[J]. Gastroenterology and Hepatology from Bed to Bench, 2019, 12(2):163-168.
    [13] COLLADO MC, DERRIEN M, ISOLAURI E, de VOS WM, SALMINEN S. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly[J]. Applied and Environmental Microbiology, 2007, 73(23):7767-7770.
    [14] LI TG, ZHANG Y, SONG JJ, CHEN LJ, DU M, MAO XY. Yogurt enriched with inulin ameliorated reproductive functions and regulated gut microbiota in dehydroepiandrosterone-induced polycystic ovary syndrome mice[J]. Nutrients, 2022, 14(2):279.
    [15] LI XJ, CHEN P, ZHANG P, CHANG YF, CUI MX, DUAN JY. Protein-bound β-glucan from Coriolus versicolor has potential for use against obesity[J]. Molecular Nutrition & Food Research, 2019, 63(7):1801231.
    [16] ROOPCHAND DE, CARMODY RN, KUHN P, MOSKAL K, ROJAS-SILVA P, TURNBAUGH PJ, RASKIN I. Dietary polyphenols promote growth of the gut bacterium Akkermansia muciniphila and attenuate high-fat diet-induced metabolic syndrome[J]. Diabetes, 2015, 64(8):2847-2858.
    [17] VERHOOG S, TANERI PE, ROA DÍAZ ZM, MARQUES-VIDAL P, TROUP JP, BALLY L, FRANCO OH, GLISIC M, MUKA T. Dietary factors and modulation of bacteria strains of Akkermansia muciniphila and Faecalibacterium prausnitzii:a systematic review[J]. Nutrients, 2019, 11(7):1565.
    [18] DRUART C, PLOVIER H, van HUL M, BRIENT A, PHIPPS KR, de VOS WM, CANI PD. Toxicological safety evaluation of pasteurized Akkermansia muciniphila[J]. Journal of Applied Toxicology:JAT, 2021, 41(2):276-290.
    [19] DEPOMMIER C, EVERARD A, DRUART C, PLOVIER H, van HUL M, VIEIRA-SILVA S, FALONY G, RAES J, MAITER D, DELZENNE NM, de BARSY M, LOUMAYE A, HERMANS MP, THISSEN JP, de VOS WM, CANI PD. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers:a proof-of-concept exploratory study[J]. Nature Medicine, 2019, 25(7):1096-1103.
    [20] TURCK D, BOHN T, CASTENMILLER J, de HENAUW S, HIRSCH-ERNST KI, MACIUK A, MANGELSDORF I, MCARDLE HJ, NASKA A, PELAEZ C, PENTIEVA K, SIANI A, THIES F, TSABOURI S, VINCETI M, CUBADDA F, FRENZEL T, HEINONEN M, MARCHELLI R, NEUHÄUSER-BERTHOLD M, et al. Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to regulation (EU) 2015/2283[J]. EFSA Journal, 2021, 19(9):e06780.
    [21] HAANEN JBAG, ROBERT C. Immune checkpoint inhibitors[M]//Progress in Tumor Research. Switzerland:S. Karger AG, 2015:55-66.
    [22] 陈顺, 仵朝晖, 解有成, 王俊科, 梁昭君, 李斌, 于晓辉. 局部进展期结直肠癌新辅助免疫治疗临床研究及应用进展[J]. 中国肿瘤临床, 2023, 50(2):92-97. CHEN S, WU ZH, XIE YC, WANG JK, LIANG ZJ, LI B, YU XH. Clinical research and application progress of neoadjuvant immunotherapy in advanced local colorectal cancer[J]. Chinese Journal of Clinical Oncology, 2023, 50(2):92-97(in Chinese).
    [23] 陈顺, 赵宝银, 贾栋, 仵朝晖, 王盼, 谢小青, 于晓辉. 免疫检查点抑制剂在肝细胞癌新辅助治疗中的研究进展[J]. 中国肿瘤临床, 2022, 49(19):1015-1020. CHEN S, ZHAO BY, JIA D, WU ZH, WANG P, XIE XQ, YU XH. Research progress of immune checkpoint inhibitors in the neoadjuvant therapy for hepatocellular carcinoma[J]. Chinese Journal of Clinical Oncology, 2022, 49(19):1015-1020(in Chinese).
    [24] RIBAS A, PUZANOV I, DUMMER R, SCHADENDORF D, HAMID O, ROBERT C, HODI FS, SCHACHTER J, PAVLICK AC, LEWIS KD, CRANMER LD, BLANK CU, O'DAY SJ, ASCIERTO PA, SALAMA AKS, MARGOLIN KA, LOQUAI C, EIGENTLER TK, GANGADHAR TC, CARLINO MS, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002):a randomised, controlled, phase 2 trial[J]. The Lancet Oncology, 2015, 16(8):908-918.
    [25] ROTHWELL B, KIFF C, LING C, BRODTKORB TH. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England[J]. PharmacoEconomics-Open, 2021, 5(2):251-260.
    [26] SALGIA NJ, BERGEROT PG, MAIA MC, DIZMAN N, HSU J, GILLECE JD, FOLKERTS M, REINING L, TRENT J, HIGHLANDER SK, PAL SK. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors[J]. European Urology, 2020, 78(4):498-502.
    [27] WEI F, ZHONG S, MA ZY, KONG H, MEDVEC A, AHMED R, FREEMAN GJ, KROGSGAARD M, RILEY JL. Strength of PD-1 signaling differentially affects T-cell effector functions[J]. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110(27):E2480-E2489.
    [28] LIANG SC, LATCHMAN YE, BUHLMANN JE, TOMCZAK MF, HORWITZ BH, FREEMAN GJ, SHARPE AH. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses[J]. European Journal of Immunology, 2003, 33(10):2706-2716.
    [29] PAUCEK RD, BALTIMORE D, LI GD. The cellular immunotherapy revolution:arming the immune system for precision therapy[J]. Trends in Immunology, 2019, 40(4):292-309.
    [30] HE DQ, LI X, AN R, WANG LH, WANG Y, ZHENG S, CHEN XQ, WANG XJ. Response to PD-1-based immunotherapy for non-small cell lung cancer altered by gut microbiota[J]. Oncology and Therapy, 2021, 9(2):647-657.
    [31] XU XJ, LV J, GUO F, LI J, JIA YT, JIANG D, WANG N, ZHANG C, KONG LY, LIU YB, ZHANG YN, LV J, LI ZX. Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway[J]. Frontiers in Microbiology, 2020, 11:814.
    [32] ZHENG Y, WANG TT, TU XX, HUANG Y, ZHANG HY, TAN D, JIANG WQ, CAI SF, ZHAO P, SONG RX, LI PL, QIN N, FANG WJ. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J]. Journal for Immunotherapy of Cancer, 2019, 7(1):193.
    [33] GRENDA A, IWAN E, CHMIELEWSKA I, KRAWCZYK P, GIZA A, BOMBA A, FRĄK M, ROLSKA A, SZCZYREK M, KIESZKO R, KUCHARCZYK T, JAROSZ B, WASYL D, MILANOWSKI J. Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer[J]. AMB Express, 2022, 12(1):86.
    [34] CASCONE T, WILLIAM WN JR, WEISSFERDT A, LEUNG CH, LIN HY, PATAER A, GODOY MCB, CARTER BW, FEDERICO L, REUBEN A, KHAN MAW, DEJIMA H, FRANCISCO-CRUZ A, PARRA ER, SOLIS LM, FUJIMOTO J, TRAN HT, KALHOR N, FOSSELLA FV, MOTT FE, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer:the phase 2 randomized NEOSTAR trial[J]. Nature Medicine, 2021, 27(3):504-514.
    [35] LEE KA, THOMAS AM, BOLTE LA, BJÖRK JR, de RUIJTER LK, ARMANINI F, ASNICAR F, BLANCO-MIGUEZ A, BOARD R, CALBET-LLOPART N, DEROSA L, DHOMEN N, BROOKS K, HARLAND M, HARRIES M, LEEMING ER, LORIGAN P, MANGHI P, MARAIS R, NEWTON-BISHOP J, et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma[J]. Nature Medicine, 2022, 28(3):535-544.
    [36] HOU XY, ZHANG P, DU HZ, CHU WH, SUN RQ, QIN SY, TIAN Y, ZHANG ZJ, XU FG. Akkermansia muciniphila potentiates the antitumor efficacy of FOLFOX in colon cancer[J]. Frontiers in Pharmacology, 2021, 12:725583.
    [37] PANEBIANCO C, ADAMBERG K, JAAGURA M, COPETTI M, FONTANA A, ADAMBERG S, KOLK K, VILU R, ANDRIULLI A, PAZIENZA V. Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice[J]. Cancer Chemotherapy and Pharmacology, 2018, 81(4):773-782.
    [38] CHEN Z, QIAN X, CHEN SS, FU XX, MA GJ, ZHANG AQ. Akkermansia muciniphila enhances the antitumor effect of cisplatin in lewis lung cancer mice[J]. Journal of Immunology Research, 2020, 2020:2969287.
    [39] WU AH, VIGEN C, TSENG C, GARCIA AA, SPICER D. Effect of chemotherapy on the gut microbiome of breast cancer patients during the first year of treatment[J]. Breast Cancer:Targets and Therapy, 2022, 14:433-451.
    [40] LIU QY, LU Y, XIAO Y, YUAN LP, HU DR, HAO Y, HAN RX, PENG JR, QIAN ZY. Effects of docetaxel injection and docetaxel micelles on the intestinal barrier and intestinal microbiota[J]. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 2021, 8(24):e2102952.
    [41] DIZMAN N, HSU J, BERGEROT PG, GILLECE JD, FOLKERTS M, REINING L, TRENT J, HIGHLANDER SK, PAL SK. Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma[J]. Cancer Medicine, 2021, 10(1):79-86.
    [42] TERRISSE S, GOUBET AG, UEDA K, THOMAS AM, QUINIOU V, THELEMAQUE C, DUNSMORE G, CLAVE E, GAMAT-HUBER M, YONEKURA S, FERRERE G, RAUBER C, PHAM HP, FAHRNER JE, PIZZATO E, LY P, FIDELLE M, MAZZENGA M, SILVA CAC, ARMANINI F, et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer[J]. Journal for Immunotherapy of Cancer, 2022, 10(3):e004191.
    [43] DAISLEY BA, CHANYI RM, ABDUR-RASHID K, AL KF, GIBBONS S, CHMIEL JA, WILCOX H, REID G, ANDERSON A, DEWAR M, NAIR SM, CHIN J, BURTON JP. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients[J]. Nature Communications, 2020, 11:4822.
    [44] SFANOS KS, MARKOWSKI MC, PEIFFER LB, ERNST SE, WHITE JR, PIENTA KJ, ANTONARAKIS ES, ROSS AE. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies[J]. Prostate Cancer and Prostatic Diseases, 2018, 21(4):539-548.
    [45] NIE XL, GENG ZX, LIU JJ, QI L, WANG ZT, LIU T, TANG JG. Chinese herbal medicine anticancer cocktail soup activates immune cells to kill colon cancer cells by regulating the gut microbiota-Th17 axis[J]. Frontiers in Pharmacology, 2022, 13:963638.
    [46] XIA T, ZHANG B, LI Y, FANG B, ZHU XX, XU BC, ZHANG J, WANG M, FANG JP. New insight into 20(S)-ginsenoside Rh2 against T-cell acute lymphoblastic leukemia associated with the gut microbiota and the immune system[J]. European Journal of Medicinal Chemistry, 2020, 203:112582.
    [47] TENG LX, WANG KY, CHEN WP, WANG YS, BI L. HYR-2 plays an anti-lung cancer role by regulating PD-L1 andAkkermansia muciniphila[J]. Pharmacological Research, 2020, 160:105086.
    [48] LIN ZM, CHEN L, CHENG MN, ZHU FH, YANG XQ, ZHAO WM, ZUO JP, HE SJ. Cortex periplocae modulates the gut microbiota to restrict colitis and colitis-associated colorectal cancer via suppression of pathogenic Th17 cells[J]. Biomedicine & Pharmacotherapy, 2022, 153:113399.
    [49] SHAO L, GUO YP, WANG L, CHEN MY, ZHANG W, DENG S, HUANG WH. Effects of ginsenoside compound K on colitis-associated colorectal cancer and gut microbiota profiles in mice[J]. Annals of Translational Medicine, 2022, 10(7):408.
    [50] WANG YS, ZHANG XD, LI JW, ZHANG Y, GUO YJ, CHANG Q, CHEN L, WANG YW, WANG SY, SONG Y, ZHAO YK, WANG ZH. Sini decoction ameliorates colorectal cancer and modulates the composition of gut microbiota in mice[J]. Frontiers in Pharmacology, 2021, 12:609992.
    [51] WANG LJ, TANG L, FENG YM, ZHAO SY, HAN M, ZHANG C, YUAN GH, ZHU J, CAO SY, WU Q, LI L, ZHANG Z. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+T cells in mice[J]. Gut, 2020, 69(11):1988-1997.
    [52] FAN LN, XU CC, GE QW, LIN YF, WONG CC, QI YD, YE B, LIAN QW, ZHUO W, SI JM, CHEN SJ, WANG LJ. A. muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like TAMs[J]. Cancer Immunology Research, 2021, 9(10):1111-1124.
    [53] PONZIANI FR, BHOORI S, CASTELLI C, PUTIGNANI L, RIVOLTINI L, del CHIERICO F, SANGUINETTI M, MORELLI D, PARONI STERBINI F, PETITO V, REDDEL S, CALVANI R, CAMISASCHI C, PICCA A, TUCCITTO A, GASBARRINI A, POMPILI M, MAZZAFERRO V. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J]. Hepatology (Baltimore, Md), 2019, 69(1):107-120.
    [54] ASHRAFIAN F, KESHAVARZ AZIZI RAFTAR S, SHAHRYARI A, BEHROUZI A, YAGHOUBFAR R, LARI A, MORADI HR, KHATAMI S, OMRANI MD, VAZIRI F, MASOTTI A, SIADAT SD. Comparative effects of alive and pasteurized Akkermansia muciniphila on normal diet-fed mice[J]. Scientific Reports, 2021, 11:17898.
    [55] OTTMAN N, REUNANEN J, MEIJERINK M, PIETILÄ TE, KAINULAINEN V, KLIEVINK J, HUUSKONEN L, AALVINK S, SKURNIK M, BOEREN S, SATOKARI R, MERCENIER A, PALVA A, SMIDT H, de VOS WM, BELZER C. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function[J]. PLoS One, 2017, 12(3):e0173004.
    [56] REUNANEN J, KAINULAINEN V, HUUSKONEN L, OTTMAN N, BELZER C, HUHTINEN H, de VOS WM, SATOKARI R. Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer[J]. Applied and Environmental Microbiology, 2015, 81(11):3655-3662.
    [57] WANG ZZ, QIN X, HU DX, HUANG J, GUO ES, XIAO RR, LI WT, SUN CY, CHEN G. Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer[J]. Cell Reports, 2022, 41(13):111890.
    [58] QU S, ZHENG YH, HUANG YC, FENG YC, XU KY, ZHANG W, WANG YW, NIE KL, QIN M. Excessive consumption of mucin by over-colonized Akkermansia muciniphila promotes intestinal barrier damage during malignant intestinal environment[J]. Frontiers in Microbiology, 2023, 14:1111911.
    [59] WANG KC, WU WR, WANG Q, YANG LY, BIAN XY, JIANG XW, LV LX, YAN R, XIA JF, HAN SY, LI LJ. The negative effect of Akkermansia muciniphila-mediated post-antibiotic reconstitution of the gut microbiota on the development of colitis-associated colorectal cancer in mice[J]. Frontiers in Microbiology, 2022, 13:932047.
    [60] MENG X, ZHANG JR, WU H, YU DH, FANG XX. Akkermansia muciniphila aspartic protease Amuc_1434* inhibits human colorectal cancer LS174T cell viability via TRAIL-mediated apoptosis pathway[J]. International Journal of Molecular Sciences, 2020, 21(9):3385.
    [61] LUO ZW, XIA K, LIU YW, LIU JH, RAO SS, HU XK, CHEN CY, XU R, WANG ZX, XIE H. Extracellular vesicles from Akkermansia muciniphila elicit antitumor immunity against prostate cancer via modulation of CD8+T cells and macrophages[J]. International Journal of Nanomedicine, 2021, 16:2949-2963.
    [62] 徐利本, 吴朝阳, 王远东. PI3K/Akt信号传导通路在肿瘤发生发展及治疗中的作用[J]. 现代肿瘤医学, 2021, 29(1):177-180. XU LB, WU CY, WANG YD. The role of PI3 K/Akt signal pathway in the development and progression of tumor[J]. Journal of Modern Oncology, 2021, 29(1):177-180(in Chinese).
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

唐海茹,解有成,李娜,王盼,于晓辉. 黏蛋白阿克曼菌辅助治疗恶性肿瘤的研究进展[J]. 微生物学报, 2023, 63(10): 3746-3757

复制
分享
文章指标
  • 点击次数:234
  • 下载次数: 746
  • HTML阅读次数: 653
  • 引用次数: 0
历史
  • 收稿日期:2023-02-20
  • 最后修改日期:2023-06-06
  • 在线发布日期: 2023-10-09
  • 出版日期: 2023-10-04
文章二维码